- No file added yet -

Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients With Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model

media

posted on 2020-11-24, 15:11 authored by Michael Willis, Andreas Nilsson, Klas Kellerborg, Philip Ball, Rupert Roe, Shana Traina, Rebecca Beale, Isabelle Newell

Article full text

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).